ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0541

Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan

Victoria Furer1, Clara Weil2, Melanie Orin2, Gabriel Chodick2, Varda Shalev2, Yonit Fisher Shoval3, Raanan Cohen3 and Ori Elkayam4, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, 3Abbvie, Hod Hasharon, Israel, 4Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

Meeting: ACR Convergence 2020

Keywords: Administrative Data, autoimmune diseases, population studies, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical societies. Yet, evidence points to a suboptimal adherence to vaccination recommendations among the AIIRD population.1-3 

The purpose of this study is to assess the vaccination coverage with influenza, pneumococcal and herpes zoster (HZ) vaccines among adult patients with AIIRD in a real-world setting.

Methods: A retrospective cross-sectional study was performed using the databases of Maccabi Healthcare Services (MHS), a large healthcare provider in Israel. The AIIRD population was defined as adults (≥ 18 years old) alive on 30/04/2019, with ≥12 months of continuous enrolment, diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE). Point prevalence rates among MHS members were age-adjusted. Optimal coverage was defined as vaccination documented in the past year for influenza and 5 years for pneumococcal (PPSV23 and/or PCV13) and HZ vaccines.

Results: A total of 14,528 AIIRD patients were included. Overall, 41.0%, 17.5%, 4.8%, and 3.6% of AIIRD patients had optimal influenza, PPSV23, PCV13 and HZ vaccination coverage, respectively (Table 1). The highest age-specific vaccination rates were observed in age group 75-79y for influenza, 65-69y for PPSV23, 55-59y for PCV13, and 70-74y for HZ respectively (Figure 2). Influenza vaccination was significantly (p< 0.05) associated with older age (≥60y) after adjusting for patient characteristics and potential confounders. Among the elderly (≥65y),  AIIRD patients had comparable vaccine coverage rates to those reported in the general population in Israel4 for influenza (past year: 63.2% vs. 61.0%) and PPSV23 (past 5y or at least once since age 65y: 83.4% vs. 77.7%). The uptake of PCV13 and HZ vaccines was remarkably low in all age groups.

Conclusion: This study provides real-world evidence of suboptimal influenza, pneumococcal, and HZ vaccination coverage of patients with AIIRD, in particular among younger adults. There remains significant scope to improve uptake of vaccinations in patients with AIIRD.

References:

  1. Hmamouchi I, et al. Vaccine 2015; 33:1446.
  2. Costello R, et al. PLoS One 2016; 11:e0153848.
  3. Subesinghe S, et al. BMC Musculoskelet Disord 2016; 17:322.
  4. Calderon-Margalit R, et al. National Program for Quality Indicators in Community Healthcare in Israel, Report 2013-2017. Jerusalem: School of Public Health and Community Medicine, Hebrew University-Hadassah; 2017.

Table 1. Vaccination coverage with influenza, pneumococcal and herpes zoster vaccines among adults diagnosed with autoimmune inflammatory rheumatic diseases (30/4/2019).

Figure 1. Age-specific optimal vaccination coverage with influenza, pneumococcal and herpes zoster vaccines among adults diagnosed with autoimmune inflammatory rheumatic diseases (30/4/2019). AIIRD, autoimmune inflammatory rheumatic diseases (defined here as rheumatoid arthritis, psoriatic arthritis, and/or systemic lupus erythematosus); PCV13, pneumococcal conjugate vaccine; PPSV23, pneumococcal polysaccharide vaccine. *Optimal coverage defined as vaccination in the past year for influenza, and vaccination in the past 5 years for pneumococcal and herpes zoster vaccines.


Disclosure: V. Furer, None; C. Weil, None; M. Orin, None; G. Chodick, None; V. Shalev, None; Y. Fisher Shoval, Abbvie, 1, 3; R. Cohen, abbvie, 1, 3; O. Elkayam, None.

To cite this abstract in AMA style:

Furer V, Weil C, Orin M, Chodick G, Shalev V, Fisher Shoval Y, Cohen R, Elkayam O. Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/suboptimal-vaccination-coverage-with-influenza-pneumococcal-and-herpes-zoster-vaccines-among-adult-patients-with-autoimmune-inflammatory-rheumatic-diseases-in-a-nationwide-health-care-plan/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/suboptimal-vaccination-coverage-with-influenza-pneumococcal-and-herpes-zoster-vaccines-among-adult-patients-with-autoimmune-inflammatory-rheumatic-diseases-in-a-nationwide-health-care-plan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology